Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

4.48
+0.31007.43%
Post-market: 4.580.0970+2.17%19:30 EDT
Volume:460.70K
Turnover:2.03M
Market Cap:452.48M
PE:-10.41
High:4.53
Open:4.19
Low:4.19
Close:4.17
52wk High:7.13
52wk Low:2.03
Shares:101.00M
Float Shares:48.17M
Volume Ratio:1.42
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4302
EPS(LYR):-0.4847
ROE:-3727.94%
ROA:-64.18%
PB:-3.25
PE(LYR):-9.24

Loading ...

Galectin Therapeutics reaches alignment with FDA on belapectin pathway

TIPRANKS
·
Jun 23

Galectin Therapeutics - to Evaluate Single 2 Mg Dose of Belapectin in Phase 3 Trial

THOMSON REUTERS
·
Jun 23

Galectin Therapeutics - FDA Accepts Galectin's Blinded Central Endoscopy Review Process

THOMSON REUTERS
·
Jun 23

Galectin Therapeutics - to File Phase 3 Protocol for Belapectin in Q3 2026 - SEC Filing

THOMSON REUTERS
·
Jun 23

Galectin Therapeutics: Positive Type C Meeting With FDA for Belapectin in Patients With Mash Cirrhosis and Portal Hypertension

THOMSON REUTERS
·
Jun 23

Galectin Therapeutics - Reaches Agreement With FDA on Primary Endpoint and Regulatory Path for Potential Full Approval of Belapectin

THOMSON REUTERS
·
Jun 23

Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension

Reuters
·
Jun 23

Galectin Therapeutics CMO Jamil Khurram sells 568 common shares for $1,761.43

Reuters
·
May 28

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 28

Galectin Therapeutics presents belapectin data at EASL 2026

TIPRANKS
·
May 27

Galectin says belapectin cuts new varices in NAVIGATE MASH cirrhosis trial analysis

Reuters
·
May 27

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis

GlobeNewswire
·
May 27

H.C. Wainwright Keeps Their Buy Rating on Galectin Therapeutics (GALT)

TIPRANKS
·
May 22

Analysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)

TIPRANKS
·
May 16

Galectin Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate

Benzinga Earnings
·
May 15

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
May 15

Galectin Therapeutics Inc: Q1 Net Loss $5.1 Million, $-0.08 per Share

THOMSON REUTERS
·
May 15

Galectin net loss narrows 47.61% to $5.05 million in Q1 FY26

Reuters
·
May 15

Galectin Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
May 11